1.  Martini E, et al.:  Brief information on an early phase II study with deprenyl in demented patients.  Pharmacopsychiatry.  20:256-7, 1987. 
2.   Evans RW, Gualtieri CT:  Psychostimulant pharmacology in traumatic brain injury.  J Head Trauma Rehabil 2(4):29-33, 1987.
3. Crisostomo EA, et al.:  Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients.  Ann Neurol 23:94-7, 1988.
4. Gualtieri CT:  Neuropsychiatry and Behavioral Pharmacology  Springer-Verlag, NY, 37-88, 1991.
5. Sloan RL, et al.:  Fluoxetine as a treatment for emotional lability after brain injury.  Brain Injury. 6:4:315-9, 1992.
6. Zee-Cheng C, et al.:  Haloperidol and torsades de pointes.  Ann Intern Med  102:418, 1985.
7. Guiltieri CT, et al.:  Clinical and neuropsychological effects of desipramine in children with attention deficit hyperactivity disorder.  J Clin Psychopharmacol 11:155-59, 1991.
8. Seliger GM, et al.:  Fluoxetine improves emotional incontinence.  Brain Injury.  6(3): 267-70.
9. Gualtieri CT, Evans RW:  Stimulant treatment for the neurobehavioral sequelae of traumatic brain injury.  Brain Injury 2:273-90, 1988.
10.  El-Mallakh RS, et al.:  The use of beta blockers in psychiatry.  Res Staff Physician. 35:4, 49-62, 1989.
11.  Johnston JA, et al.:  A 102 center prospective study of siezures in association with bupropion.  J Clin Psychiatry. 52(11): 450-6, 1991.
12.  Gupta SR, Mlcoch AG:  Bromocriptine treatment of nonfluent aphasia.  Arch Phys Med Rehabil 73:373-6, 1992.
13.
14.
15.  Reinhard DL, et al.:  Improved arousal and initiation following tricyclic antidepressant use in severe brain injury.  Arch Phys Med Rehabil 77:80-3, 1996.
16.  Wood RL:  Rehabilitation of patients with disorders of attention.  J Head Trauma Rehabil 1:43-53, 1986. 
17.  Wroblewski BA, Leary JM, Phelan AM, et al.: Methylphenidate and seizure frequency in brain injured patients with seizure disorders.  J Clin Psychiatry  1992;53:86-89.
18.  Rothman KJ, et al.:  Bromocriptine and puerperal siezures. Epidemiology.  1(3):232-8, 1990.
19.  Dimsdale JE:  Reflections on th impact of antihypertensive medications on mood, sedation, and neuropsychologic functioning.  Arch Intern Med 152:35-9, 1992.
20.  Wroblewski BA, et al.:  The incidence of siezures during tricyclic antidepressant drug treatment in a brain injured population.  J Clin Psychopharmacol 10:124-8, 1990.
21.  Ojemann LM, et al.:  Effect of doxepin on siezure frequency in depressed epileptic patients.  Neurology 33:646-8, 1983.
22. Haig AJ, Ruess JM:  Recovery from vegetative state of six month's duration associated with sinemet (levodopa/carbidopa).  Arch Phys Med Rehabil  71:1081-3, 1990.
23.
24.  Garrison SJ, Henson HK:  Dilantin toxicity and vegetative depression:  A report of two cases.  Arch Phys Med Rehabil 71:422-3, 1990.
25.  Nickels JL, et al.:  Clinical use of amantadine in brain injury rehabilitation.  Brain Injury 8(8):709-18, 1994.
28.  Reekum RV, et al.:  N of 1 study:  Amantadine for the amotivational syndrome in a patient with traumatic brain injury.  Brain Injury  9(1):49-53, 1995.
29.  Cowell LC, Cohen RF:  Amantadine:  A potential adjuvant therapy following traumatic brain injury.  J Head Trauma Rehabil 10(6):91-4, 1995.
30.  Boyeson MG, Harmon RL:  Effects of trazodone and desipramine on motor recovery in brain-injured rats.  Am J Phys Med Rehabil 72:286-93, 1993.
31.  Speech TJ, et al.:  A double-blind controlled study of methylphenidate treatment in closed head injury.  Brain Injury 7(4):333-8, 1993.
32.  Macchio GJ, et al.:  Amantadine-induced coma.  Arch Phys Med Rehabil 74:1119-20, 1993.
33.  Zasler ND:  Bromocriptine: Neuropharmacology and clinical caveats.  J Head Trauma Rehabil 10(4):101-4,  1995.
34.  Glenn MB:  CNS stimulants:  applications for traumatic brain injury.  J Head Trauma Rehabil 1(4):74-6, 1986.
35.  Kaelin DL, et al.:  Methylphenidate effect on attention deficit in the acutely brain-injured adult.  Arch Phys Med Rehabil 77:6-9, 1996.
37.  Bosker G, Albrich JM:  Emergency detection of adverse drug reactions in the elderly.  Res Staff Physician 75-91, 1989.
38.  Feeney DM, et al.:  Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury.  Science 217:855-7, 1982.
39.  Rao N, et al.:  Agitation in closed head injury: Haloperidol effects on rehabilitation outcome.  Arch Phys Med Rehabil 66:30-4, 1985.
40.  Jackson T, et al.:  Torsade de pointes and low-dose oral haloperidol.  Arch Intern Med 157:2013-5, 1997.
41.  Evans RW, Gualtieri CT:  Carbamazepine: A neuropsychological and psychiatric profile.  Clin Neuropharmacol 8:221-41, 1985.
42.  Greenhill LL:  Pharmacologic treatment of attention deficit hyperactivity disorder.  Pediatric Psychopharmacology 15(1):1-27, 1992.
43.  Wroblewski BA:  Epileptic potential of stimulants, dopaminergics, and antidepressants.  J Head Trauma Rehabil 7(3):109-11, 1992.
44.  Evans RW, et al.:  Treatment of chronic closed head injury with psychostimulant drugs:  A controlled case study and an appropriate evaluation procedure.  J Nerv and Mental Disease 175(2):106-110, 1987.
45. Whyte J, et al.:  Quantification of attention-related behaviors in individuals with traumatic brain injury.  Am J Phys Med Rehabil 73:2-9, 1994.
46.  Starr MS:  The role of dopamine in epilepsy.  Synapse 22:159-94, 1996.
50. Ockey RR, et al.:  Use of sinemet in locked-in syndrome: A report of two cases. Arch Phys Med Rehabil 76:868-70, 1995.
52.  Wroblewski BA, Glenn MB:  Pharmacological treatment of arousal and cognitive deficits.  J Head Trauma Rehabil 9:19-42, 1994.
53.  Atchison JW, et al.:  Hyponatremia-associated cognitive impairment in traumatic brain injury.  Brain Injury 7(4):347-52, 1993.
54.  Clifford DB, et al.:  Acute effects of antidepressants on hippocampal siezures.  Ann Neurol 18: 692-7, 1985.
55.  Cardenas DD, McLean A Jr.:  Psychopharmacologic management of traumatic brain injury.  In Phys Med Rehabil Clinics N. America 3(2):273-90, 1992.
56.  Damouji NF, Ferfuson JM:  Trazodone induced delirium in bulemic patients.  Am J Psychiatry 141(3):434, 1984.
57.  Bleiberg J, et al.:  Cognitive assessment and therapy in traumatic brain injury.  In Phys Med Rehabil State Art Reviews 3(1):95-121, 1989.
58.  Mysiw WJ, et al.: Tricyclic antidepressant therapy after traumatic brain injury.  J Head Trauma Rehabil 2(4):34-42, 1987.
59.  Cassidy JW:  Update on pharmacology:  Fluoxetine a new seratonergically active depressant.  J Head Trauma Rehabil 4(2): 67-9, 1989.
60.  Casey DA:  Obsessive-compulsive disorder.  Postgraduate Medicine 91(2):171-4, 1992.
61.  Yudofsky SC, Hales RE:  Am Psychiatric Press Textbook of Neuropsychiatry, second ed., Am.  Psych. Press Inc., Washington DC, 663-701, 1992.
62.  Bamford CR, et al.:  Serial epilepsy caused by levodopa/carbidopa administration in two patients on hemodialysis.  Intern J Neuroscience 50:209-14, 1990.
63.  McPherson A:  Convulsive seizures and electroencephalogram changes in three patients during levodopa therapy.  Neurology 20:41-5, 1970.
64.  Gualtieri CT, et al.:  Amantadine: a new clinical profile for traumatic brain injury.  Clin Neuropharmacol 12(4):258-70, 1989.
65.  Stern JM:  Cranio-cerebral injured patients.  Scand J Rehabil Med 10:7-10, 1978.
66.  Shields WD, et al.:  Amantadine in the treatment of refractory epilepsy in childhood: an open trial in 10 patients.  Neurology 35:579-81, 1985.
67.  Muller-Schwefe G, Penn RD: Physostigmine in the treatment of intrathecal baclofen overdose.  J Neurosurg 71:273-5, 1989.
68.  Lowe TL, et al:  Stimulant medications precipitate Tourette's syndrome.  JAMA 247:1729-31, 1982.
69.  Lal S, et al.:  Modification of function in head-injured patients with Sinemet.  Brain Injury 2(3):225-33, 1988.
70.  Catsman-Berrevoets CE, Harskamp F:  Compulsive pre-sleep behavior and apathy due to bilateral thalamic stroke: response to bromocriptine.  Neurology 38:647-9, 1988.
71.  Cope DN:  An integration of psychopharmacological and rehabilitation approaches to traumatic brain injury rehabilitation.  J Head Trauma Rehabil 9(3):1-18, 1994.
72.  Hovda DA, Feeney DM:  Amphetamine and experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat.  Brain Res 298:358-61, 1984.
73.  Guttman M:  Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease.  Neurology 49:1060-5, 1997.
74.  Sussman N:  Diagnosis and drug treatment of anxiety in the elderly.  Geriatr Med Today. 7:37-51, 1992.
75.  Stange KC, et al.:  Adverse reactions to amantadine prophylaxis of influenza in a retirement home.  J Am Geriatr Soc 33:700-5, 1991.
76.  Eames P:  The use of Sinemet and bromocriptine.  Brain injury 3:319-20, 1989.
77.  Lader M:  Assessing the potential for buspirone dependence or abuse and effects of its withdrawl.  Am J Med 82(Suppl 5A):20-6, 1987.
78.  Franson KL, et al.:  Drug induced seizures in the elderly.  Causative agents and optimal management.  Drugs & Aging 7(1):38-48, 1995. 
79.  Bleiberg J, et al.:  Effects of dexedrine on performance consistency following brain injury.  Neuropsychiatry Neuropsychol Behav Neurol 6:245-8, 1993.
80.  van Woerkom TCAM and Minderhoud JM:  Pharmacologic interventions.  Phys Med and Rehabil: State of Art Rev  4(3):447-64, 1990.
81.  Jabbari B, et al.:  Incidence of seizures with tricyclic and tetracyclic antidepressants.  Arch Neurol 42:480-1, 1985.
82.  Erkulwater S and Pillai R:  Amantadine and the end stage dementia of Alzheimer's type.  Southern Medical Journal 82:550-4, 1989.
83.  Speech TJ, et al.:  A double-blind control study of methylphenidate treatment in closed head injury.  Brain Injury 7:333-8, 1993.
84.  Horiguchi J, et al.:  Effects of long term amantadine treatment of clinical symptoms and EEG of a patient in a vegetative state.  Clin Neuropharmacol 13:84-8, 1990.
85.  Evans RW, et al.:  Methylphenidate and memory:  Dissociated effects in hyperactive children.  Psychopharmacology 90:211-6, 1986.
86.  Wilcox JA, Tsuang J:  Psychological effects of amantadine on psychotic subjects.  Neuropsychobiology 23(3):144-6, 1990-1.
87.  Chandler MC, et al.:  Case studies: amantadine for the agitated head-injury patient.  Brain Injury 2:309-11, 1988.
89.  Dimsdale JE, et al.:  Neuropsychological side effects of beta-blockers.  Arch Intern Med 149:514-25, 1989.
90.  Barrett K:  Treating organic abulia with bromocriptine and lisuride: four case studies.  J Neurol Neurosurg Psychiatry 54:718-22, 1991.
91.  Cantello R, et al.:  Analgesic action of methylphenidate on Parkinsonian sensory symtoms.  Arch Neurol 45:973-6, 1988.
92.  Roca RP, et al.:  Improvements in activity and appetite among long-term care patients with amantadine: 
a clinical report.  J Am Geriatr Soc 38:675-7, 1990.
93.  Dubois B, et al.:  Slowing of cognitive processing in progressive supranuclear palsy.  Arch Neurol 45:1194-9, 1988.
94.  Hunt N, Stern TA:  The association between intravenous haloperidol and torsades de pointes:  three cases and a literature review.  Psychosomatics.  36:541-9, 1995.
95.  Schmidt HS, et al.:  Protriptyline:  an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia.  Am J Psychiatry 134:183-5, 1977.
96.  Elovic E, Antoinette T:  Principles of neurochemistry and neuropharmacology.  Phys Med Rehabil Clin North Am 8(4):605-27, 1997.
97.  Leino O:  Open trial with levodopa-carbidopa conbination to patients with long-standing progressive myoclonus epilepsy.  Acta Neurol Scand 63:389-95, 1981.
98.  Eames P:  The use of Sinemet and bromocriptine.  Brain Injury 3(3):319-20, 1989.
100.  Miller LG, Jankovic J:  Metoclopramide-induced movement disorders.  Arch Intern Med 149:2486-92, 1989.
101.  Snoey ER, Bessen HA:  Acute psychosis after amantadine overdose.  Ann Emerg Med 19:668-70, 1990.
102.  Ross ED, Stewart RM:  Akinetic mutism from hypothalamic damage: successful treatment with dopamine agonists.  Neurology 31:435-9, 1981.
103.  Matthews CG, Harley JP:  Cognitive and motor-sensory performances in toxic and nontoxic epileptic subjects.  Neurology 25:184-8, 1975.
104.  Devinsky O, et al.:  Akinetic mutism in a bone marrow transplant recipient following total body irradiation and amphotericin B chemoprophylaxis.  Arch Neurol 44:414-7, 1987.
105.  Lipka LJ, Lathers CM:  Psychoactive agents, seizure production, and sudden death in epilepsy.  J Clin Pharmacol 27:169-83, 1987.
106.  Whyte J:  Toward rational psychopharmacological treatment:  Integrating research and clinical practice.  J Head Trauma Rehabil 9(3):91-103, 1994.
107.  Van Reekum R, et al.:   N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury.  Brain Injury 9(1):49-53, 1995.
108.  Grimes JD, et al.:  Long-term follow-up of tardive dyskinesia due to metoclopramide.  Lancet 2:563, 1982.
109.  Zametkin A, et al.:  Treatment of hyperactive children with monoamine oxidase inhibitors.  Arch Gen Psychiatry 42:962-6, 1985.
110.  O'Dougherty M, et al.:  Carbamazepine plasma aconcentration - relationship to cognitive impairment.  Arch Neurol 44:863-7, 1987.
111.  Sylvia LM, et al.:  Aseptic meningitis associated with naproxen.  Drug Intell Clin Pharm 22:399-401, 1988.
112.  Stewart JT, et al.:  Treatment of a case of akinetic mutism with bromocriptine.  J Neuropsychiatry Clin Neurosci 2(4):462-3, 1990.
113.  Kriwisky M, et al.:  Haoloperidol-induced torsades de pointes.  Chest 98:482-4, 1990.
114.  Wroblewski B, et al.:  Protriptyline as an alternative stimulant medication in patients with brain injury:  a series of case reports.  Brain Injury 7(4):353-62, 1993.
116.Bleiberg J, et al.:  Cognitive assessment and therapy in traumatic brain injury.  Phys Med and State Art Rev 3(1):95-121, 1989.
117.  Bullard DE:  Diencephalic siezures: responsiveness to bromocriptine and morphine.  Ann Neurol 21:609-11, 1987.
119.  Lipper S, Tuchman MM:  Treatment of chronic post-traumatic organic brain syndrome with dextroamphetamine:  first reported case.  J Nerv Ment Dis 162:366-71, 1976.
120.  McNeny R, Zasler ND:  Neuropharmacologic remediation of hemi-attention following brain injury.  NeuroRehab 1:72-8, 1991.
121.  Lawson JM, Grady MJ:  Ibuprofen-induced aseptic meningitis in a previously healthy patient.  West J Med 143:386-7, 1985.
122.  Marin RS, et al.:  Apathy a treatable syndrome.  Neuropsychiatry 7:23-30, 1995.
123.  Plenger PM, et al.:  Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury:  a preliminary double-blind placebo controlled study.  Arch Phys Med Rehabil 77:536-40, 1996.
124.  Sartori M, et al.:  Torsade de pointes:  malignant cardiac arrhythmia induced by amantadine poisoning.  Am J Med 77:388-91, 1984.
125.  Widener HL, Littman BH:  Ibuprofen-induced meningitis in systemic lupus erythematosus.  JAMA 239:1062-4, 1978.
126.  Horn AC, Jarrett SW:  Ibuprofen-induced aseptic meningitis in rheumatoid arthritis.  Ann Pharmacother 31:1009-11, 1997.
127.  Codding C, et al.:  Aseptic meningitis in association with diclofenac treatment in a patient with systemic lupus erythematosus.  Arthritis Rheum 34:1340-1, 1991.
129.   Fleet WS, et al.:  Dopamine agonist therapy for neglect in humans.  Neurology 37:1765-70, 1987.
130.  Ruppert GB, Barth WF:  Tolmetin-induced aseptic meningitis.  JAMA 245:67-8, 1981.
131.  Thompson PJ, Trimble MR:  Anticonvulsant serum levels: relationship to impairments of cognitive functioning.  J Neurology, Neurosurg, and Psychiatry 46:227-33.
132.  Drug Evaluation, 6th ed., American Medical Association, Chicago, pg. 180, 1986.
133.  Whyte J, et al.:  Effects of methylphenidate on attentional function after traumatic brain injury.  Am J Phys Med Rehabil 76:440-50, 1997.
134.  Crisostomo EA, et al.:  Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients.  Ann Neurol 23:94-7, 1988.
135.  Shukla S, et al.:  Mania following head trauma.  Am J Psychiatry 144:93-6, 1987.
136.  Carlson J, Wiholm B:  Trimethoprim associated aseptic meningitis.  Scand J Infect Dis 19:687-91, 1987.
137.  Mooney GF, Haas LJ:  Effect of methylphenidate on brain injury-related anger.  Arch Phys Med Rehabil 74:153-60, 1993.
138.  Drake RE, Ehrlih J:  Suicide attempts associated with akathisia.  Am J Psychiatry 142:499-501, 1985.
139.  Stewart J:  Akathisia following traumatic brain injury: treatment with bromocriptine.  J Neurol Neurosurg Psychiatry 52:1200-3, 1989.
140.  Gallassi R, et al.:  Carbamazepine and phenytoin - comparison of cognitive effects in epileptic patients during monotherapy and withdrawal.  Arch Neurol 45:892-4, 1988.
141.  Carvey PM, et al.:  Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.  J Neural Transm 104:209-28, 1997.
143.  Andrews DG, et al.:  A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy.  Epilepsia 27:128-34, 1986.
144.  Pulaski KH, Emmett L:  The combined intervention of therapy and bromocriptine mesylate to improve functional performance after brain injury.  Am J Occup Ther 48(3):263-70, 1994.
145.   Chase JE, Gidal BE:  Melatonin: therapeutic use in sleep disorders.  Ann Pharmacother 31:1218-26, 1997.
146.  Kurlan R, Dimitsopulos T:  Selegiline and manic behavior in Parkinson's disease.  Arch Neurol 49:1231, 1992.
147.  Hutton JT, et al.:  Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.  Arch Neurol 45:861-4, 1988.
148.  Dillin W, Uppal GS:  Analysis of medications used in the treatment of cervical disk degeneration.  Ortho Clin North Am 23(3):421-33, 1992.
149.  Worzniak M, et al.:  Methylphenidate in the treatment of coma.  J Fam Pract 44:495-8, 1997.
150.  Berrol S:  Evolution and the persistent vegetative state.  Head Trauma Rehabil 1(1):7-13, 1986.
151.  Sitland-Marken PA, et al.:  Psychiatric applications of bromocriptine therapy.  J Clin Psychiatry 51:68-82, 1990.
152.  Dodrill CB, Troupin AS:  Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin.  Neurology 27:1023-8, 1977.
153.  Jennett B, Plum F:  Persistent vegetative state after brain damage.  Lancet 1:734-7, 1972.
154.  Ingvar DH, et al.:  Survival after severe cerebral anoxia with destruction of the cerebral cortex:  The apallic syndrome.  Annals NY Acad Sci 57:184-208, 1978.
155.  Bartkowski HM, Lovely MP:  Prognosis in coma and the persistent vegetative state.  Head Trauma Rehabil 1(1):1-5, 1986.
156.  Kareken DA, et al.:  Functional Brain Imaging in Apraxia.  Arch Neurol 55:107-14, 1998.
157.  Glenn MB:  Post-comatose unawareness.  Brain Injury 6(1):101-2, 1992.
158.  Thompson PJ, Trimble MR:  Anticonvulsant drugs and cognitive functions.  Epilepsia 23:531-44, 1982.
159.  Samie MR, et al.:  Life-threatening tardive dyskinesia caused by metoclopramide.  Movement Disorders 2(2):125-9, 1987.
160.  Fry JM:  Treatment modalities for narcolepsy.  Neurology 50(Suppl 1):S43-S48, 1998.
161.  Habib MH, Galaburda AM:  Motor and motivational disorders in limbic-paralimbic lesions. In Joseph AB and Young  RR (ed.) Movement Disorders in Neurology and Neuropsychaiatry Blackwell Scientific Publications (Boston) 350-62, 1992.
162.  Jenner P:  The rationale for the use of dopamine agonists in Parkinson's disease.  Neurology 45(suppl3):S6-S12, 1995.
163.  Berger L, et al.:  Akinetic mutism and Parkinsonism associated with obstructive hydrocephalus.  Can J Neurol Sci 12:255-8, 1985.
164.  Schleissner LA:  Glutethimide intoxication with prolonged coma and hyperpyrexia treated with methylphenidate.  California Medicine 105(1):41-4, 1966.
165.  Anderson B:  Relief of akinetic mutism from obstructive hydrocephalus using bromocriptine and ephedrine.  J Neurosurg 76:152-5, 1992.
166.  Stewart JT, et al.:  Treatment of a case of akinetic mutism with bromocriptine.  J of Neuropsychiatry 2(4):462-3, 1990.

EVERY PATIENT DESERVES A CHANCE!!!